

Patient: [REDACTED]
 DOB: [REDACTED] Age: 46 Sex: M
 Patient Identifiers: [REDACTED]
 Visit Number (FIN): [REDACTED]

Client: [REDACTED]
 Physician: [REDACTED]

ARUP Test Code: 2007479
 Collection Date: [REDACTED]
 Received in Lab: 12/09/2023
 Completion Date: 12/10/2023

Patient Results - Current *

| | |
|------------------------------|--------------------|
| Collection Date | [REDACTED] |
| Creatinine, Urine | 130.2 |
| Methadone Screen, U | Negative |
| Tramadol Screen, U | Negative |
| Cocaine Screen, U | Negative |
| Barbiturates Screen, U | Negative |
| Ethyl Glucuronide Screen, U | Negative |
| Phencyclidine Screen, U | Negative |
| Carisoprodol Screen, U | Negative |
| Morphine, U | Present |
| Buprenorphine, U | Present |
| Norbuprenorphine, U | Present |
| Fentanyl, U | Present |
| Norfentanyl, U | Present |
| Amphetamine, U | Present |
| Methamphetamine, U | Present |
| Lorazepam, U | Present |
| Naloxone, U | Present |
| THC (Cannabinoids) Screen, U | PresumptiveP OS |
| ARUP Accession | 23-278-153808 |

* For details, see report on following page.

NOTE: Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult the patient's prior charts.




Patient: [REDACTED]
 ARUP Accession: 23-278-153808

Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: [REDACTED] | Date of Birth: [REDACTED] | Sex: M | Physician: [REDACTED]
 Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

| Drug Analyte | Result | Cutoff | Notes |
|--|-----------------|-----------|---|
| OPIOIDS, IMMUNOASSAY | | | |
| Methadone | Negative | | |
| Tramadol | Negative | | |
| COCAINE, IMMUNOASSAY | | | |
| Benzoylcegonine | Negative | | cocaine metabolite |
| BARBITURATES, IMMUNOASSAY | | | |
| Barbiturates | Negative | | detects amobarbital, butalbital, pentobarbital, phenobarbital, secobarbital, and others |
| OTHERS (IMMUNOASSAY OR SPECTROPHOTOMETRY) | | | |
| Ethyl glucuronide | Negative | | ethanol metabolite |
| Marijuana metabolite | Presumptive POS | | 9-carboxy-tetrahydrocannabinol; does not distinguish between prescribed and illicit forms |
| PCP | Negative | | phencyclidine |
| Carisoprodol | Negative | 100 ng/mL | detects carisoprodol and meprobamate |
| OPIATES, MASS SPEC | | | |
| Codeine | Not Detected | | |
| Morphine | Present | | also a metabolite of Codeine; may reflect poppy seed ingestion |
| 6-acetylmorphine | Not Detected | | heroin metabolite; morphine is expected |
| OXYCODONE-LIKE, MASS SPEC | | | |
| Oxycodone | Not Detected | | |
| --Noroxycodone | Not Detected | | oxycodone metabolite |
| Oxymorphone | Not Detected | | eg, Opana; also a metabolite of oxycodone |
| --Noroxymorphone | Not Detected | | oxymorphone metabolite; naloxone metabolite (i.e., nornaloxone) |
| Hydrocodone | Not Detected | | also a minor metabolite of Codeine; possible impurity of oxycodone |
| --Norhydrocodone | Not Detected | | hydrocodone metabolite |
| Hydromorphone | Not Detected | | eg, Dilaudid; also a metabolite of hydrocodone, and a minor metabolite of morphine |
| OPIOIDS, MASS SPEC | | | |
| Buprenorphine | Present | | eg Suboxone, Subutex |
| --Norbuprenorphine | Present | | buprenorphine metabolite |
| Fentanyl | Present | | |
| --Norfentanyl | Present | | fentanyl metabolite |
| Meperidine metabolite | Not Detected | | normeperidine |



Patient: [REDACTED]
 ARUP Accession: 23-278-153808

Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: [REDACTED] | Date of Birth: [REDACTED] | Sex: M | Physician: [REDACTED]
 Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

| Drug Analyte | Result | Cutoff | Notes |
|---------------------------------------|----------------|--------------------|--|
| Tapentadol | Not Detected | | |
| --Tapentadol-o-sulfate | Not Detected | | tapentadol metabolite |
| OPIOIDS ANTAGONIST, MASS SPEC | | | |
| Naloxone | Present | | eg, Narcan; also coformulated in Suboxone |
| GABA ANALOGUES, MASS SPEC | | | |
| Gabapentin | Not Detected | | |
| Pregabalin | Not Detected | | eg, Lyrica |
| AMPHETAMINE-LIKE, MASS SPEC | | | |
| Amphetamine | Present | | eg, Vyvanse; also a metabolite of methamphetamine |
| Methamphetamine | Present | | d- and l- isomers are not distinguished by this test; may reflect Vicks inhaler, Desoxyn, Selegiline, or illicit source |
| MDMA - Ecstasy | Not Detected | | |
| MDA | Not Detected | | also a metabolite of MDMA and MDEA |
| MDEA - Eve | Not Detected | | |
| Phentermine | Not Detected | | |
| Methylphenidate | Not Detected | | eg, Ritalin, Dexmethylphenidate, Focalin, Concerta |
| BENZODIAZEPINE-LIKE, MASS SPEC | | | |
| Alprazolam | Not Detected | | eg, Xanax |
| --Alpha-hydroxyalprazolam | Not Detected | | alprazolam metabolite |
| Clonazepam | Not Detected | | eg, Klonopin |
| --7-aminoclonazepam | Not Detected | | clonazepam metabolite |
| Diazepam | Not Detected | | eg, Valium |
| Nordiazepam | Not Detected | | metabolite of chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam, halazepam (Alapryl), prazepam (Centrax) and others |
| Oxazepam | Not Detected | | eg, Serax; also metabolite of nordiazepam and temazepam |
| Temazepam | Not Detected | | eg, Restoril; also a metabolite of diazepam |
| Lorazepam | Present | | eg, Ativan |
| Midazolam | Not Detected | | eg, Versed |
| --Alpha-OH-Midazolam | Not Detected | | midazolam metabolite |
| Zolpidem | Not Detected | | eg, Ambien |
| --Zolpidem Metabolite | Not Detected | | zolpidem 4-phenyl carboxylic acid |
| | | Reference interval | |
| Creatinine value (mg/dL) | 130.2 | 20.0 - 400.0 mg/dL | |



Patient: [REDACTED]
 ARUP Accession: 23-278-153808

Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: [REDACTED] | Date of Birth: [REDACTED] | Sex: M | Physician: [REDACTED]
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

Interpretive Comments

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not fit clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available at an additional fee within two weeks of specimen collection.

For medical purposes only; not valid for forensic use.

For further information, consult aruplab.com/pain.

Please call ARUP Laboratories at 800-522-2787 for Medical Director consultation or assistance with interpretation if needed.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Additional Information

METHODOLOGIES USED

- Qualitative Enzyme Immunoassay
- Qualitative Liquid Chromatography-Tandem Mass Spectrometry
- Quantitative Spectrophotometry

ABBREVIATIONS

- MASS SPEC - Mass Spectrometry
- MDA - 3,4-methylenedioxyamphetamine
- MDEA - 3,4-methylenedioxy-N-ethylamphetamine
- MDMA - 3,4-methylenedioxy-N-methylamphetamine

